You are here

Article Text

Article menu
Download PDFPDF
Letter
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis
  1. E Kruithof1,
  2. P Kestelyn2,
  3. C Elewaut3,
  4. D Elewaut1,
  5. F Van den Bosch1,
  6. H Mielants1,
  7. E M Veys1,
  8. F De Keyser1
  1. 1Department of Rheumatology, Ghent University Hospital, Belgium
  2. 2Department of Ophthalmology, Ghent University Hospital
  3. 3Dendermonde, Belgium
  1. Correspondence to:
    Dr E Kruithof, Department of Rheumatology, OK12IB Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium;
    elli.kruithof{at}rug.ac.be

https://doi.org/10.1136/ard.61.5.470

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A nterior and intermediate uveitis are inflammatory processes of diverse causes, including among others, infections, trauma, lymphoproliferative disorders, and ischaemia. The remainder are considered to have an immune pathogenesis with an autoimmune component. For example, uveitis is a common manifestation of spondyloarthropathy (SpA), a related group of disorders, with common clinical, biological, genetic, and therapeutic characteristics.1 Within the SpA group of diseases, considerable overlap between the different disease entities can occur—for example, during the course of ankylosing spondylitis, 40% of the patients will develop acute anterior uveitis (AUU).2 In addition, in patients with AUU, SpA is the most commonly identified systemic disease.3 Moreover, as is true for other diseases within the SpA group, …

    View Full Text